Itgam-IRES-DTRGFP

Fig.1 Schematic representation of dosing regimen. Blood samples were taken from the orbital venous plexus before dosing.

Fig.2 Survival rate of Itgam-IRES-DTRGFP mice treated with DT. 

Fig.3 The percent of CD11b⁺ and other immune cells in peripheral blood of HO Itgam-IRES-DTRGFP mice is detected by FACS. 

Myeloid cells were significantly reduced 48 hours (D2) after 1st DT administration, and returned 72 hours (D5) after the 2nd DT treatment. However, macrophages were not significantly cleared after DT treatment.

Fig.4 Detection of GFP expression in mCD11b⁺/mCD14⁺/mF4/80⁺ cells in Peripheral blood in WT C57BL/6 and HO Itgam-IRES-DTRGFP (C57BL/6)  KI mice in Day 0.

Fig.5 Detection of GFP expression in mCD11b⁺/mCD14⁺/mF4/80⁺ cells in Peripheral blood in WT C57BL/6 and HO Itgam-IRES-DTRGFP (C57BL/6)  KI mice in Day 2.

Fig.6 Detection of GFP expression in mCD11b⁺/mCD14⁺/mF4/80⁺ cells in Peripheral blood in WT C57BL/6 and HO Itgam-IRES-DTRGFP (C57BL/6)  KI mice in Day 5.